Experience

Davis Polk advised the underwriters in connection with the SEC-registered offering by The Medicines Company of 5,227,273 shares of common stock for approximately $172.5 million, which…

Davis Polk advised Banco Santander, S.A. in connection with its SEC-registered offering of $1.5 billion aggregate principal amount of 2.706% senior preferred fixed-rate notes due 2024 and …

Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Bain Capital, the controlling shareholder of Notre Dame Intermédica, of 60,000,000…

Davis Polk is advising Morgan Stanley & Co. LLC as financial adviser to AbbVie Inc. in connection with its approximately $63 billion acquisition of Allergan plc. The transaction is…

Davis Polk advised the lead manager, sole book-runner and representative of the several underwriters in connection with Bank of America Corporation’s $1.3975 billion SEC-registered offering…

Davis Polk is advising I Squared Capital on its sale of Cube Hydro Partners and its affiliate, Helix Partners, to Ontario Power Generation. The transaction is expected to close in the…

Davis Polk advised WPEngine, Inc. on its acquisition of Fancy Chap, Inc. (d/b/a Flywheel), a Delaware corporation. The transaction closed on June 25, 2019. WPEngine is a WordPress Digital…

Davis Polk advised the initial purchasers in connection with a Rule 144A and Regulation S offering by YY Inc. (NASDAQ: YY) of $425 million aggregate principal amount of 0.750% convertible…

Davis Polk advised the representatives of the several underwriters in connection with the $125 million initial public offering of common stock by Atreca, Inc. The common stock is listed on…

Davis Polk advised Ballantyne Re plc and its foreign representative in connection with an Irish scheme of arrangement that successfully restructured over $1.6 billion of claims with over 98…